

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
25 June 2015 (25.06.2015)

(10) International Publication Number
WO 2015/091851 A1

- (51) **International Patent Classification:**
CUP 17/18 (2006.01)
- (21) **International Application Number:**
PCT/EP2014/078552
- (22) **International Filing Date:**
18 December 2014 (18. 12.2014)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
2013 1718 20 December 2013 (20. 12.2013) NO
- (71) **Applicant:** XELLIA PHARMACEUTICALS APS
[DK/DK]; Dalslandsgate 11, DK-2300 K0benhavn S (DK).
- (72) **Inventors:** HANSEN, Espen Fridtjof; Slalamveien 80B,
N-3050 Lommedalen (NO). KLEMSDAL, Havard; Eke-
bergveien 213D, N-1 162 Oslo (NO).
- (74) **Agent:** ONSAGERS AS; P.O. BOX 1813 Vika, N-0123
Oslo (NO).
- (81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))



WO 2015/091851 A1

(54) **Title:** PROCESS FOR THE PREPARATION OF TIACUMICIN

(57) **Abstract:** The present invention relates to the preparation of Tiacumicin B from a *Dactylosporangium* or *Actinoplanes* strain capable of producing Tiacumicin B utilizing spray drying or freeze drying and further extraction of the dried powder.

Process for the preparation of Tiacumicin

The present invention relates to an improved process for the preparation and purification of Tiacumicin B. Specifically, the invention relates to a purification of
5 Tiacumicin B from a dried fermentation broth, followed by extraction and chromatography techniques: The process according to the invention is simpler than the processes according to the prior art, and can easily be used on a large scale for commercial production.

10 Tiacumicin B can be produced as disclosed in US4918174 or WO2004014295.

Summary of the invention

The present invention concerns a process for preparing Tiacumicin B comprising the steps of drying a fermentation broth prior to extraction with a suitable solvent.

15

In particular, the present invention provides a process for the preparation of Tiacumicin B comprising the steps of:

- 20 a) fermentation of a Tiacumicin B producing strain;
- b) drying the fermentation broth;
- c) extraction of the dried material with a solvent.

The drying step b) according to the present invention may be performed by spray drying or freeze drying.

25 According to one embodiment, the solvent used according to the present method is selected from the group consisting of C₁-C₅ alcohols, C₄-C₆ ethers, C₂-C₅ ketones or C₂-C₅ esters.

30 According to yet an embodiment, the solvent is selected from the group consisting of methanol, ethanol, isopropanol and acetone.

The solvent used according to the present method may furthermore comprise water, such as e.g. at least 1-40% v/v water, such as e.g. at least 10-30% v/v water, or such as e.g. at least 15-20% v/v water. Such solvents, are referred to in the present
35 disclosure as aqueous solvents.

According to one embodiment, a process for preparing Tiacumicin B is provided, comprising the steps of:

- 40 a) fermentation of a Tiacumicin B producing strain;
- b) drying the fermentation broth;

- c) extraction of the dried material with an aqueous solvent comprising 50-90% v/v of an organic solvent selected from the group consisting of methanol, ethanol, isopropanol and acetone.

- 5 According to another embodiment, a process is provided comprising the steps of:
- a) fermentation of a *Dactylosporangium* or *Actinoplanes* strain capable of producing Tiacumicin B;
 - b) drying the fermentation broth;
 - 10 c) extraction of the dried material with an aqueous solvent comprising 60-90% v/v methanol and ethanol.

The extraction may be performed with a solvent selected from the group consisting of methanol, ethanol, isopropanol and acetone. According to one embodiment, the solvent is an aqueous solvent comprising 50-90 % v/v methanol, ethanol,
15 isopropanol or acetone.

The solvent used according to the present invention may according to one embodiment be an aqueous solvent comprising 60-90% v/v, preferably 70 - 80% v/v, more preferably 75% v/v of an organic solvent. Said solvent may be selected
20 from the group consisting of methanol, ethanol, isopropanol and acetone.

According to yet another embodiment, the drying is performed by spray drying and the aqueous solvent used in the extraction step is 70-80% v/v methanol. According to yet another embodiment, the drying is performed by spray drying and the
25 aqueous solvent used in the extraction step is 70-80% v/v ethanol.

According to yet another embodiment, the drying is performed by freeze drying and the aqueous solvent used in the extraction step is 70-80% v/v methanol. According to yet another embodiment, the drying is performed by freeze drying and the
30 aqueous solvent used in the extraction step is 70-80% v/v ethanol.

The ratio between solvent volume to dried fermentation broth mass according to the present method may be 1-6 ml/g. According to one embodiment of the present invention, the ratio between solvent volume to dried fermentation broth mass is 2-4
35 ml/g.

According to the present invention, the Tiacumicin B producing strain to be used in the fermentation step may be selected from the group consisting of
40 *Dactylosporangium* and *Actinoplanes*.

The various aspects and more of the present invention, including various embodiments, will be described in further detail, with reference to the detailed description, examples and appended drawings.

Figures:

Figure 1 shows the extraction efficiency at different solvent concentration of a spray dried fermentate.

5 Figure 2 shows the extraction yield at different methanol concentration of a spray dried fermentate.

Figure 3 shows the yield when extracting a spray dried fermentate at different volumes of 75% v/v aqueous methanol.

10 Detailed description:

According to the present invention, any Tiacumicin B producing bacterial strain may be used to provide the fermentation broth according to the present invention. According to one embodiment, Tiacumicin B can be produced by fermentation of *Dactylosporangium aurantiacum* subspecies hamdenensis NRRL 18085 or
15 *Actinoplanes deccanensis* ATCC 21983.

The fermentation broth is the liquid nutrient medium comprising the bacterial biomass and the Tiacumicin compounds.

20 The drying of the fermentation broth can be performed by freeze drying. A preferred freeze drying process includes reducing the temperature to -40°C and the pressure to 200 mTorr, then performing a primary drying at a temperature in the range -5°C to 5°C and thereafter secondary drying at a temperature of about 20°C.

25 The preferred drying process for the fermentation broth according to the present invention is spray drying. Despite the high temperature in the spray drying process, Tiacumicin B can be recovered in high yield.

30 A preferred spray drying process includes an in-let temperature of 180-220 °C and an out-let temperature of 80-100 °C. The drying is performed to achieve a water content of 0%-12% w/w, more preferred is a water content of less than 10% w/w; e.g. 2%-8% w/w.

35 C₁-C₅ alcohols are meant to embrace the aliphatic alcohols having 1, 2, 3, 4 or 5 carbon atoms.

C₄-C₆ ethers are meant to embrace the aliphatic ethers having 4, 5 or 6 carbon atoms.

40 C₂-C₅ ketones are meant to embrace the aliphatic ketones having 2, 3, 4 or 5 carbon atoms.

C₂-C₅ esters are meant to embrace the aliphatic esters having 1, 2, 3, 4 or 5 carbon atoms.

5 According to one embodiment, the dried fermentation broth is extracted with a solvent selected from the group consisting of methanol, ethanol, isopropanol and acetone.

10 According to another embodiment, the dried fermentation broth is extracted with an aqueous solvent comprising 50-90% v/v of an organic solvent selected from the group consisting of methanol, ethanol, isopropanol and acetone, preferably 70 - 80% v/v, more preferably 75% v/v of an organic solvent selected from the group consisting of methanol, ethanol, isopropanol and acetone. The preferred pH during extraction is about 5-7, preferably 6-7, more preferably 7. The preferred temperature during extraction is 20-25°C.

15 The methanol or ethanol concentration in the extraction solution is subsequently adjusted by evaporation or dilution to a concentration suitable for binding of tiacumicin B on an adsorption resin, e.g. 50% organic solvent in water. After binding on an adsorption resin, the resin is washed with an aqueous solvent solution to remove unbound impurities, e.g. 50% organic solvent. The bound tiacumicin B can be eluted with a solvent comprising 60-100% organic solvent and 0-40 v/v water.

25 **Experimental data:**

Example 1

Dactylosporangium aurantiacum subspecies hamdenensis NRRL 18085 fermentate was spray dried directly using a Niro Mobile Minor spray dryer with a 2-fluid nozzle. The air pressure was 1.2 bar. Inlet-temperature was ca. 200°C and outlet temperature was 90-92°C. The feeding rate was 0.5-1.0 liters per hour.

30 The spray dried powder was divided into eight 5ml volumetric flasks with ca. 1 g in each. Solvent was then added up to the 5ml mark. Different solvents were used: ethanol, methanol, isopropanol, n-propanol, acetonitrile, acetone, dimethyl sulfoxide, water. The flasks were shaken in an overhead stirrer for one hour. The slurry was withdrawn and centrifuged. The resulting supernatant was analyzed by HPLC. DMSO was the most efficient solvent in the extraction. However, DMSO is not suitable for production scale due to e.g. high boiling point. Surprisingly, methanol gave highest yield of the other solvents. The yield was 50-100 % higher compared to ethanol, isopropanol, n-propanol, acetonitrile and acetone.

40 Example 2

Spray dried *Dactylosporangium aurantiacum* subspecies hamdenensis NRRL 18085 fermentate was extracted with different solvents and different solvent/water

compositions. Ethanol, methanol, isopropanol and acetone were used with concentrations of 100%, 75%, 50% and 25% in water. Five times the weight of the dry fermentate was used in volume (i.e. 200 mg powder pr. ml solution). The slurries were shaken in an overhead shaker for four hours. The slurry was
5 centrifuged, and the supernatant was analyzed by HPLC. The results are shown in figure 1.

Example 3

Spray dried *Dactylosporangium aurantiacum* subspecies hamdenensis NRRL 18085
10 fermentate was extracted with methanol of different concentrations in water. 1 g fermentate was transferred to a 5ml measuring flask, and methanol/water solution was added to the mark. Concentrations of 65%, 70%, 75%, 80% and 85% methanol in purified water (RO) were tested. The slurries were shaken in an overhead shaker for 1.5 hours. The slurries were centrifuged, and the supernatants were analyzed by
15 HPLC. The dry weights of the supernatants were also determined. The results are shown in figure 2.

There was a peak in the extraction yield at 75-80% methanol. The dry weight decreased with increasing methanol concentration. The HPLC purity remained the
20 same with all methanol concentrations.

Example 4

Spray dried *Dactylosporangium aurantiacum* subspecies hamdenensis NRRL 18085
25 fermentate was extracted with different volumes of 75% methanol/water. 1 g of fermentate was added 2, 3, 4, 5, and 10 ml 75% methanol in different tubes. The slurries were shaken in an overhead shaker for 1.5 hours. The slurries were centrifuged, and the supernatants were analyzed by HPLC.

The results are shown in figure 3. The yield was similar for all volumes.
30

Example 5

Spray dried *Dactylosporangium aurantiacum* subspecies hamdenensis NRRL 18085
35 fermentate was extracted with 75% methanol/water (3 times the weight in volume) under stirring for two hours. The slurry was centrifuged, and concentrated two times in a rotary evaporator to give 50% methanol in the solution. The concentrate was loaded directly on a HP20 resin packed in a column. The column was washed with 50% methanol and eluted with a gradient from 50% to 100% methanol. The yield was 92%.

40 Example 6

The drying step of the present invention may be performed by freeze drying both in small and large scale as shown in the below examples.

6.1 Small scale freeze drying

4 L *Dactylosporangium aurantiacum* subspecies hamdenensis NRRL 18085 fermentate was poured into to steel trays (height of liquid 1.5-2.0 cm). The trays were mounted in a Virtis Genesis 12ES freeze dryer and frozen to -40°C. After reaching the mentioned temperature they were let standing for two hours. Then the condenser was cooled to ca -50°C and a vacuum of 200 mTorr was established. The shelf temperature was adjusted to -5°C during 600 min. Then the shelf temperature was quickly adjusted to 0°C and kept for 1250 min. Another quick adjustment of the shelf temperature to +5°C was performed, and the product was kept at this temperature for 600 min. The secondary drying was performed by quick adjustment to +20°C upon which the product was left for 1250 min at vacuum (200mTorr). Then the tanks were removed from the freeze dryer and 179 g dry material was obtained.

6.2 Large scale freeze drying

Ca 110 L *Dactylosporangium aurantiacum* subspecies hamdenensis NRRL 18085 fennentate was poured into 48 steel trays (height of liquid 1.5-2.0 cm). The trays were placed in two freeze dryers, and frozen to -20°C. After reaching the mentioned temperature, the fennentate was left standing for a while. The condenser was cooled to ca -40°C. Then a vacuum of ca 200 mTorr was established. The shelf temperature was adjusted to +40°C during ca 44 hours. Then the trays were removed from the freeze dryer and 6.6 kg dry material was obtained.

400 g of freeze dried *Dactylosporangium aurantiacum* subspecies hamdenensis NRRL 18085 fennentate was added 2000 ml 80% v/v methanol-water and stirred for 1 hour. Then the mixture was centrifuged at 4500rpm for 15min. The supernatant was decanted (volume of 1550 ml). The sediment was added 1400 ml 80 % v/v methanol-water. The mixture was left over night and stirred for 1 hour the next day. Then it was centrifuged at 4500 rpm for 15min. The supernatant was decanted (volume of 1380ml). Both supernatants were combined to a total volume of 2930 ml. Total yield 79%.

The solution was then evaporated under reduced pressure on a 40°C water bath. The final volume was 1220 ml comprising 40% water as measured by Karl Fisher titration. This solution was loaded on a column packed with a HP20 resin.

CLAIMS

1. A process for the preparation of Tiacumicin B comprising the steps of:
 - a) fermentation of a Tiacumicin B producing strain;
 - b) drying the fermentation broth;
 - c) extraction of the dried material with a solvent.
2. A process according to claim 1, wherein the broth is spray dried or freeze dried.
3. A process according to claim 1, wherein the broth is spray dried.
4. A process according to claim 1, wherein the broth is freeze dried.
5. A process according to claim 1, wherein the solvent is selected from of C₁-C₅ alcohols, C₄-C₆ ethers, C₂-C₅ ketones or C₂-C₅ esters.
6. A process according to claim 1, wherein the solvent is selected from methanol, ethanol, isopropanol and acetone.
7. A process according to claim 5 or 6, wherein the solvent further comprises water.
8. A process according to claim 5 or 6, wherein the solvent further comprises 1-40% v/v water.
9. A process according to claim 5 or 6, wherein the solvent further comprises 10-30% v/v water.
10. A process according to claim 5 or 6, wherein the solvent further comprises 15-20% v/v water.
11. A process according to any of the above claims, further comprising a chromatography step involving loading of the extraction solution on a column comprising a hydrophobic adsorbent resin, optionally washing before elution.
12. A process according to claim 11 wherein the hydrophobic adsorbent resin is HP20, HP21, HP20SS, SP20, SP20SS, SP825, SP850, SP207, XAD2, XAD7HP, XAD16, XAD16HP, XAD1600, XAD 1180, IRC50 or XAD18.

Figure 1




Figure 2





Figure 3:



INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2014/078552

A. CLASSIFICATION OF SUBJECT MATTER
INV. C12P17/18
 ADD.
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal , WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	wo 2004/014295 A2 (OPTIMER PHARMACEUTICALS INC [US]; SHUE YOUE-KONG [US]; DU CHI -JEN FRAN) 19 February 2004 (2004-02-19) cited in the applicati on claims; examples -----	1-12
Y	US 4 918 174 A (MCALPINE JAMES B [US] ET AL) 17 April 1990 (1990-04-17) cited in the applicati on col umn 7, lines 10-45 -----	1-12
Y	wo 97/36996 A2 (GIST BROCADES BV [NL]; BIJL HENDRI K LOUIS [NL]; SCHAAP ALBERT [NL]; VI) 9 October 1997 (1997-10-09) page 8, line 27 - page 9, line 1; claims ----- -/- .	1-12

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 12 February 2015	Date of mailing of the international search report 19/02/2015
--	---

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Boeker, Ruth
--	---

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2014/078552

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	wo 02/06203 AI (DSM NV [NL] ; DOES THOMAS V D [NL] ; BOOIJ JOHANNES [NL] ; KERS ERNST EDM) 24 January 2002 (2002-01-24) c l a i m s ; e x a m p l e s -----	1-12

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/EP2014/078552
--

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
wo 2004014295	A2	19-02-2004	AU 2003251902 AI 25- 02-2004
			CA 2494742 AI 19- 02-2004
			CN 1688707 A 26- 10-2005
			DK 1539977 T3 17-11 -2014
			EP 1539977 A2 15- 06-2005
			ES 2527052 T3 20- 01-2015
			JP 2005534332 A 17-11 -2005
			JP 2010178760 A 19-08 -2010
			JP 2013208131 A 10-10 -2013
			KR 20050053598 A 08-06 -2005
			SI 1539977 T1 30-01 -2015
			US 2006257981 AI 16- 11-2006
			US 2010028970 AI 04-02 -2010
			US 2013123477 AI 16-05 -2013
			US 2014296498 AI 02-10 -2014
			Wo 2004014295 A2 19-02 -2004
US 4918174	A	17-04-1990	NONE
wo 9736996	A2	09-10-1997	AR 006424 AI 25-08 -1999
			AT 249514 T 15-09 -2003
			AU 733734 B2 24-05 -2001
			AU 2505097 A 22-10 -1997
			CA 2250575 AI 09-10 -1997
			CA 2579516 AI 09-10 -1997
			CN 1226923 A 25-08 -1999
			CN 1715394 A 04-01 -2006
			CN 101928213 A 29-12 -2010
			CN 102304036 A 04-01 -2012
			CN 102351678 A 15-02 -2012
			CN 104017734 A 03-09 -2014
			DE 69724782 D1 16-10 -2003
			DE 69724782 T2 01-07 -2004
			DK 0906414 T3 26-01 -2004
			EP 0906414 A2 07-04 -1999
			EP 1369474 AI 10-12 -2003
			EP 2264142 A2 22-12 -2010
			ES 2205202 T3 01-05 -2004
			ID 16503 A 02-10 -1997
			JP 4545235 B2 15-09 -2010
			JP 4958729 B2 20-06 -2012
			JP 2002502233 A 22-01 -2002
JP 2008054691 A 13-03 -2008			
JP 2010099075 A 06-05 -2010			
JP 2011004765 A 13-01 -2011			
JP 2013252148 A 19-12 -2013			
wo 9736996 A2 09-10 -1997			
ZA 9702706 A 22-10 -1997			
wo 0206203	AI	24-01-2002	AU 7113401 A 30-01-2002
			wo 0206203 AI 24-01-2002